Initial award recognizes potential of proprietary Owlstone Medical technology for non-invasive viral and bacterial respiratory infectious disease detection.
Provides insight and scientific context into VOC molecules, supporting biomarker discovery through incorporation into Owlstone’s Breath Biopsy OMNI platform.
Blood-based liquid biopsy test analyzes DNA methylation pattern of cell-free DNA (cfDNA), indicating presence of hepatocellular carcinoma as early as Stage I.